Evaluation of Umbilical Cord Derived Wharton’s Jelly For Regenerative Medicine Applications

Introduction: Musculoskeletal injuries have traditionally been treated with activity-modification, physical therapy, pharmacological agents and surgical procedures. These modalities have limitations, as well as potential side-effects. Over the last decade, there has been an increased interest in the use of biologics for regenerative medicine applications (RMA), including umbilical cord (UC) derived Wharton’s Jelly (WJ). Despite this increase, there is insufficient literature assessing the amount of growth factors, cytokines, hyaluronic acid and extracellular vesicles including exosomes in these products. The purpose of this study was to develop a novel WJ formulation and to evaluate the presence of growth factors, cytokines, hyaluronic acid (HA) and extracellular vesicles (EV) including exosomes.

2019-10-18T00:20:39+00:00